<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03787459</url>
  </required_header>
  <id_info>
    <org_study_id>CAP-China Arbidol</org_study_id>
    <nct_id>NCT03787459</nct_id>
  </id_info>
  <brief_title>Severe Influenza Trial of ARbidol</brief_title>
  <acronym>STAR</acronym>
  <official_title>Oseltamivir and Arbidol Combination Antiviral Therapy Versus Oseltamivir Monotherapy for the Treatment of Severe inﬂuenza: a Multicentre, Double-blind, Randomised Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomised, double-blind, controlled study to assess the efficacy and
      safety of arbidol plus oseltamivir, compared with oseltamivir alone in approximately 200
      hospitalized adults and adolescent patients with confirmed severe influenza. Patients should
      be randomised as soon as possible after screening (no later than 12 hours), providing they
      are within 7 days of symptom onset. Patients will be assigned in a 1:1 ratio to receive an
      arbidol plus oseltamivir, or oseltamivir plus placebo. Rescreening of patients who fail to
      meet the inclusion and exclusion criteria will be permitted only once, providing the time
      from symptom onset to randomization is still within 7 days.

      Arbidol/placebo will be administrated as 200mg TID from Days 1-7. Oseltamivir will be
      administered as 75mg twice daily from Days 1-7 (dose to be adjusted for renal impairment).
      Oseltamivir could be continued till influenza PCR negative. Both drugs, along with the
      corresponding placebo for arbidol, will be started at the time of randomization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint was time to clinical status improvement (the event) up to 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>the event defined as seven-category ordinal scale of clinical status after enrolment decrease by two category or discharged</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>oseltamivir plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oseltamivir plus arbidol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbidol</intervention_name>
    <description>Oseltamivir plus Arbidol will be administrated from Days 1-7.</description>
    <arm_group_label>oseltamivir plus arbidol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Oseltamivir plus placebos will be administrated from Days 1-7.</description>
    <arm_group_label>oseltamivir plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalized males or females with a positive PCR test for influenza virus infection

          2. Age ≥16 years at the time of signing Informed Consent Form

          3. Arterial oxygen saturation (SaO2)/ pulse oxygen saturation (SPO2) ≤94% in room air
             condition

          4. ≤ 7 days since symptom onset. The onset of symptoms is defined as either: Time of the
             first increase in body temperature (an increase of at least 1ºC from normal body
             temperature- ≥38℃); Time when the patient experiences at least one general or
             respiratory symptom.

          5. Willingness to use contraception for 7 days after the end of treatment

        Exclusion Criteria:

          1. Physicians make a decision that trial involvement is not in patients' best interest,
             or any condition that does not allow the protocol to be followed safely.

          2. Patient refusal to accept invasive organ support treatment if needed

          3. More than 3 consecutive doses of NAIs within 2 days before enrolment (including
             oseltamivir, zanamivir, peramivir)

          4. Women who are pregnant (including a positive pregnancy test at enrolment),
             breastfeeding, or within 2 weeks post-partum.

             The following female subjects do not need to undergo a pregnancy test at enrolment: a.
             Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more
             and confirmed by a follicle-stimulating hormone test) women. b. Women who are
             surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation.

          5. Any condition requiring renal replacement therapy

          6. Severe liver disease (Child-Pugh score ≥ C)

          7. A history of hypersensitivity to arbidol or oseltamivir (Tamiflu®)

          8. Currently or have been involved in another anti-influenza treatment trial in the last
             28 days

          9. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Cao, MD</last_name>
      <phone>+8684206264</phone>
      <email>caobin_ben@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yeming Wang, MD</last_name>
      <phone>+8618810663558</phone>
      <email>wwyymm_love@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 22, 2018</study_first_submitted>
  <study_first_submitted_qc>December 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Bin Cao</investigator_full_name>
    <investigator_title>China-Japan Friendship Hospital</investigator_title>
  </responsible_party>
  <keyword>severe influenza, arbidol, oseltamivir, ordinal scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Dear Sir/Madam Our study receives a grant from China Ministry of Science and Technology. We cannot decide whether the data could be shared. Hope you can understand.
Best</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

